BitMEX Introduces Most Rewarding Crypto ‘Earn’ Product Yet
Global cryptocurrency trading platform BitMEX announced the launch of BitMEX EARN. This interest-bearing product offers the highest annual percentage rate (APR) of all public Earn products.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211130005722/en/
This table comparison is accurate as of 30 November 2021 at 12 PM HKT/4AM UTC and assumes the highest APR. (Photo: Business Wire)
The product rewards users who subscribe their funds for a set period with an interest payout, ranging from 14 - 100% APR. Furthermore, BitMEX EARN is the only product of its type in the market that is 100% insurance fund backed. All payouts are guaranteed by the BitMEX insurance fund - one of the largest funds in the industry.
The first cryptocurrency available on BitMEX EARN is Tether (USDT ERC-20). BitMEX customers who subscribe to the product before 7 December 2021 can subscribe to an early bird offer to earn up to a 100% APR on Tether for deposits up to USDT 1,000 per user and up to 14% APR for deposits up to USDT 100,000 per user. More details on BitMEX EARN can be found here.
Alexander Höptner, Chief Executive Officer at BitMEX, said: “BitMEX EARN allows anyone to easily generate a double-digit return - much higher than the rates you'll get with TradFi products. Our EARN products' APR far outpaces what's offered on other crypto platforms, whose headline rates on similar products are usually tied to unattainable staking requirements. We've also streamlined our subscription process, making this a product that appeals to all kinds of traders - not just the pros.”
BitMEX EARN is part of its ambitious business transformation, known as its 'Beyond Derivatives' strategy. BitMEX is adding five new global business segments (Spot, Brokerage, Custody, Information Products, and Academy) after having launched a rigorous user verification and compliance programme in 2020. In January 2021, BitMEX announced the completion of its user verification programme, which made BitMEX one of the largest crypto derivatives exchanges to have a fully verified active user base. BitMEX EARN follows the company’s introduction of USDT for margin and settlement on perpetual swaps in November 2021.
BitMEX EARN launches on 1 December 2021, with subscriptions open for the first two products until 7 December 2021 (or until fully subscribed). To subscribe or learn more, visit the BitMEX EARN webpage.
About BitMEX
BitMEX is a trading platform that offers investors access to the global digital currency financial markets. BitMEX is owned by HDR Global Trading Limited. To learn more about BitMEX, our vision, growing team, and the road ahead, please follow us on Twitter, Telegram, and the BitMEX Blog. For further inquiries, please contact press@bitmex.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211130005722/en/
Contact information
Taylor Bossung, press@bitmex.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release
Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 16:04:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B cell-mediated diseases. Pove is the only BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases. Next Steps for Pove Development In IgAN Following the announcement that the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to pove for the treatment of IgAN, FDA recently granted a rolling review of the Biologics License Application (BLA) for pove for this indication. Vertex expects to submit the first module to FDA for potential accelerated approval before t
Qualcomm Announces Quarterly Cash Dividend17.10.2025 16:00:00 EEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
Illumynt Reports Q3 2025 Business Update17.10.2025 15:39:00 EEST | Press release
Q3 2025 was a busy quarter once again for us here at illumynt. In addition to naming a new CEO, we executed on a number of initiatives that are propelling our organization forward. Revenue for the quarter exceeded $30 million- keeping us on track for our 2025 plan. More importantly we executed three different large-scale data center decommission projects with almost no material ending up as scrap. All of the AI-focused enterprise equipment and components recovered from the decommissions were resold at top market value. We head into Q4 with high expectations and our eyes wide open. We’re celebrating the 20-year anniversary of our facility in Hong Kong and looking to add another location in the region to help us process inbound AI data center equipment. Stay tuned for updates. There will be more on the way. View source version on businesswire.com: https://www.businesswire.com/news/home/20251017446548/en/
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom